[go: up one dir, main page]

WO2002066982A3 - Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer) - Google Patents

Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer) Download PDF

Info

Publication number
WO2002066982A3
WO2002066982A3 PCT/EP2002/001781 EP0201781W WO02066982A3 WO 2002066982 A3 WO2002066982 A3 WO 2002066982A3 EP 0201781 W EP0201781 W EP 0201781W WO 02066982 A3 WO02066982 A3 WO 02066982A3
Authority
WO
WIPO (PCT)
Prior art keywords
proteins
ubiquitin
demodification
modification
related proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/001781
Other languages
English (en)
French (fr)
Other versions
WO2002066982A2 (de
WO2002066982A8 (de
WO2002066982A1 (de
Inventor
Frauke Melchior
Ulrike Gaertner
Tanja Buesgen
Marion Schergaut
Sowmya Swaminathan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften
Publication of WO2002066982A2 publication Critical patent/WO2002066982A2/de
Publication of WO2002066982A1 publication Critical patent/WO2002066982A1/de
Publication of WO2002066982A8 publication Critical patent/WO2002066982A8/de
Publication of WO2002066982A3 publication Critical patent/WO2002066982A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Die Erfindung betrifft Verfahren zur Analyse von Modifizierungen von Proteinen mit Ubiquitin-verwandten Proteinen und von Demodifizierungen von Proteinen, die mit Ubiquitin-verwandten Proteinen verknüpft sind. Desweiteren betrifft die Erfindung Verfahren zum Bestimmen von Stoffen, die diese Modifizierungen bzw. Demodifizierungen beeinflussen, sowie Verfahren zum Nachweis eines Defekts in diesen Modifizierungen bzw. Demodifizierungen. Schließlich betrifft die Erfindung ein Verfahren zur Identifizierung von Zielproteinen für die Modifizierung mit Ubiquitin-verwandten Proteinen als auch Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung. Darüber hinaus betrifft die Erfindung einen Kit, ein Fusionsprotein, eine Zelle und ein Isopeptidase-Substrat und deren Verwendungen in der Analytik und/oder Diagnostik von Ubiquitin-verwandten Modifizierung bzw. Demodifizierungen von Protein.
PCT/EP2002/001781 2001-02-21 2002-02-20 Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer) Ceased WO2002066982A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2001108263 DE10108263A1 (de) 2001-02-21 2001-02-21 Analyse von Modifizierungen und Demodifizierungen von Proteinen mit Ubiquitinverwandten Proteinen mittels FRET (Fluorescence Resonance Energy Transfer)
DE10108263.0 2001-02-21

Publications (4)

Publication Number Publication Date
WO2002066982A2 WO2002066982A2 (de) 2002-08-29
WO2002066982A1 WO2002066982A1 (de) 2002-08-29
WO2002066982A8 WO2002066982A8 (de) 2002-10-31
WO2002066982A3 true WO2002066982A3 (de) 2002-12-27

Family

ID=7674947

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001781 Ceased WO2002066982A1 (de) 2001-02-21 2002-02-20 Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer)

Country Status (2)

Country Link
DE (1) DE10108263A1 (de)
WO (1) WO2002066982A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979551B2 (en) * 2000-04-03 2005-12-27 Rigel Pharmaceuticals, Inc. Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
US6740495B1 (en) 2000-04-03 2004-05-25 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay
US20040053324A1 (en) * 2002-08-30 2004-03-18 Brian Wong Assays and compositions for identifying agents that modulate the activity of deubiquitinating agents
CA2524130A1 (en) * 2003-05-14 2004-12-02 Exelixis, Inc. Ranbp2 as modifier of the pten/igf pathway and methods of use
US20090263821A1 (en) * 2004-12-01 2009-10-22 Proteologics, Inc. Ubiquitin Ligase Assays And Related Reagents
JP2009513681A (ja) * 2005-10-28 2009-04-02 インヴィトロジェン コーポレーション キナーゼおよびユビキネーションアッセイ法
DE102014203266B4 (de) 2014-02-24 2018-07-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Zusammensetzung mit FRET-Paar in definierter Geometrie
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CN108285918A (zh) * 2017-01-09 2018-07-17 复旦大学 一种蛋白体外sumo化修饰快速检测试剂盒
US11604186B2 (en) * 2018-10-17 2023-03-14 Molecular Devices (Austria) GmbH Real time western blot assays utilizing fluorescence resonance energy transfer (FRET)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075145A2 (en) * 2000-04-03 2001-10-11 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001075145A2 (en) * 2000-04-03 2001-10-11 Rigel Pharmaceuticals, Inc. Ubiquitin ligase assay

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
GONZALEZ J E ET AL: "INTRACELLULAR DETECTION ASSAYS FOR HIGH-THROUGHPUT SCREENING", CURRENT OPINION IN BIOTECHNOLOGY, LONDON, GB, vol. 9, no. 6, December 1998 (1998-12-01), pages 624 - 631, XP000874867, ISSN: 0958-1669 *
LEE GENE W ET AL: "Modification of Ran GTPase-activating protein by the small ubiquitin-related modifier SUMO-1 requires Ubc9, an E2-type ubiquitin-conjugating enzyme homologue.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 11, 13 March 1998 (1998-03-13), pages 6503 - 6507, XP001084135, ISSN: 0021-9258 *
MELCHIOR FRAUKE: "SUMO: Nonclassical ubiquitin.", ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, vol. 16, 2000, 2000 Annual Reviews 4139 El Camino Way, Palo Alto, CA, 94303-0139, USA, pages 591 - 626, XP001087642, ISSN: 1081-0706 *
PICHLER ANDREA ET AL: "The nucleoporin RanBP2 has SUMO1 E3 ligase activity.", CELL, vol. 108, no. 1, 11 January 2002 (2002-01-11), January 11, 2002, pages 109 - 120, XP001084134, ISSN: 0092-8674 *
SCHERGAUT MARION ET AL: "SUMO1 mediated interaction between RanGAP1 and RanBP2.", MOLECULAR BIOLOGY OF THE CELL, vol. 11, no. Supplement, December 2000 (2000-12-01), 40th American Society for Cell Biology Annual Meeting;San Francisco, CA, USA; December 09-13, 2000, pages 152a, XP001085270, ISSN: 1059-1524 *
STACK JEFFREY H ET AL: "A ubiquitin-based tagging system for controlled modulation of protein stability", NATURE BIOTECHNOLOGY, NATURE PUB. CO, NEW YORK, NY, US, vol. 18, no. 12, December 2000 (2000-12-01), pages 1298 - 1302, XP002191582, ISSN: 1087-0156 *

Also Published As

Publication number Publication date
DE10108263A1 (de) 2002-09-05
WO2002066982A8 (de) 2002-10-31
WO2002066982A1 (de) 2002-08-29

Similar Documents

Publication Publication Date Title
EP1348713A3 (de) Markierungsstoffe und Markierungsprozesse zur Bestimmung von Nukleinsäuren
WO2004055519A3 (en) Specific markers for pancreatic cancer
WO2001042502A3 (en) Methods for disease detection
WO2005050224A3 (en) Small molecule and peptide arrays and uses thereof
DE602007011937D1 (de) Peptidantikörperdepletion und anwendung zur probenvorbereitung für massenspektrometrie
WO2004063704A3 (en) Vitamin d assay
EP2266996A3 (de) Markierungsstrategie für die empfindliche Detektion von Analyten
EP2287618A3 (de) Verfahren zur Diagnose neurodegenerativer Erkrankungen
WO2004057336A3 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
WO2002093129A3 (en) Methods for analyzing interactions between proteins in live and intact cells
WO2002066982A8 (de) Analyse von modifizierungen und demodifizierungen von proteinen mit ubiquintin-verwandten proteinen mittels fret (fluorescence resonance energy transfer)
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
AU2003260457A1 (en) A method and kit for the quantitative and/or qualitative detection of components in a sample
WO2005019831A3 (en) Methods for reducing complexity of a sample using small epitope antibodies
EP1560025A3 (de) Marker spezifisch für Diabetes
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
WO2005124356A3 (en) Use of protein cbp2 as a marker for colorectal cancer
ATE427494T1 (de) Verfahren zur quantifizierung der akt-protein- expression
WO2004113574A3 (en) Methods for disease screening
WO2002016947A3 (en) Methods and kits for separation and detection of proteins in biological samples
WO2006053251A3 (en) Method of measuring amyloid-beta peptides
WO2006004958A3 (en) Detection or measurement of antibodies to antigenic proteins in biological tissues or samples
WO2002090989A3 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
ATE383418T1 (de) Verfahren und zusammensetzungen zur bestimmung glycierter proteine
WO2005040806A3 (en) Use of protein asc as a marker for breast cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 35/2002 REPLACE "A1" BY "A2" AND UNDER "PUBLISHED", REPLACE "WITH INTERNATIONAL SEARCH REPORT" BY "WITHOUT INTERNATIONAL SEARCH REPORT"

Free format text: PAT. BUL. 35/2002 REPLACE "A1" BY "A2" AND UNDER "PUBLISHED", REPLACE "WITH INTERNATIONAL SEARCH REPORT" BY "WITHOUT INTERNATIONAL SEARCH REPORT"

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP